Highest-materiality recent filing
Insulet voluntary correction for ~7M Omnipod Pods due to cannula tear, up to $50M cost
~7M Pods affected (60% consumed/expired); 24 serious adverse events (hospitalization/DKA), no deaths.
Insulet adopts exclusive forum bylaws; shareholders elect directors and approve Say-on-Pay
Amended bylaws designate Delaware Chancery Court as exclusive forum for derivative and fiduciary duty claims.
Insulet Q1 revenue $761.7M (+33.9%), beats guidance; raises FY revenue outlook
Q1 revenue $761.7M, up 33.9% YoY (30.1% constant currency), exceeding guidance range of 25-27% constant currency.
On March 12, 2026, Insulet issued a press release regarding a voluntary Medical Device Correction with 18 Serious Adverse Events reported.
Insulet voluntarily corrects Omnipod 5 pods; 18 serious adverse events, up to $40M cost
Voluntary medical device correction for specific lots of Omnipod 5 Pods due to small tear in internal tubing causing under-delivery of insulin.
Insulet finalizes severance with ex-CFO Chadwick; no new material terms
Severance agreement signed Feb 27, 2026 with former CFO Ana M. Chadwick.
Insulet finalizes auditor change: Grant Thornton out, PwC in for FY2026
Grant Thornton completed its audit for FY2025; dismissal effective Feb 18, 2026.
Insulet Q4 revenue $783.8M (+31%), full year $2.7B (+31%); Board ups buyback by $350M
Q4 revenue $783.8M (+31.2% YoY) exceeded constant-currency guidance of 25-28%.
Insulet extends supply agreement with NXP USA through 2026, amends terms
Extended purchase agreement with NXP USA for period Jan 1-Dec 31, 2026.
Insulet dismisses Grant Thornton, appoints PwC as auditor for FY 2026
Audit Committee approved PwC as independent auditor for FY 2026, subject to client acceptance; Grant Thornton dismissed.
Plan clarifies 'for Cause' definition and expands clawback/recoupment language.
Insulet Q3 EPS $1.24 beats; revenue up 30% YoY; raises FY guidance
Revenue $706.3M (+29.9% YoY), exceeding 22-25% constant-currency guidance range.
Insulet appoints former JPMorgan investment banking chair Robbie Huffines to board
Robbie Huffines appointed as independent Class II director, effective October 31, 2025.
Insulet appoints Flavia Pease as CFO effective Sept 30; expects to exceed Q3 revenue guidance
Ana Chadwick departs as CFO; Flavia Pease, former Charles River Labs CFO, assumes role on Sept 30, 2025.
Insulet Q2 revenue $649M (+32.9%), beats guidance; raises full-year outlook
Revenue $649.1M, up 32.9% YoY (31.3% constant currency), above 26% constant-currency guidance.
Insulet refinances $481.25M term loan at lower rate, redeems 0.375% convertible notes due 2026
Refinanced $481.25M term loans with new term loans at 0.50% lower interest rate margin (2.00% for Term SOFR loans).
Insulet shareholders approve 2025 equity plan adding 7.4M shares; all director nominees elected
2025 Stock Option and Incentive Plan approved (59.9M for, 3.3M against), authorizing 7.4M new shares.
Insulet Q1 revenue up 29% YoY to $569M, raises guidance; new CEO
Revenue $569M (+28.8% YoY) exceeds high end of guidance; Omnipod revenue $554.1M (+28%).
Insulet appoints Ashley McEvoy CEO, expects Q1 revenue above guidance, raising FY outlook
Ashley McEvoy appointed President and CEO effective April 28; succeeds Jim Hollingshead, who resigned from Board.
Insult Corp CTO Mark Field departs March 14; signs consulting deal through Aug 31, 2025
Mark Field departed as SVP & CTO effective March 14, 2025.
Issued $450M aggregate principal of 6.50% Senior Notes due 2033; net proceeds ~$444M.
Insulet proposes $450M notes offering to refinance 2026 convertibles; seeks $200M revolver increase
Proposed $450M senior unsecured notes due 2033 in private placement to QIBs and non-US persons.
Insulet prices $450M senior notes at 6.50% due 2033 to refinance convertible notes
$450M aggregate principal of senior unsecured notes due 2033, priced at 6.50% annual interest.
Insult CTO Mark Field departs effective March 14; Amit Guliani named acting CTO
Mark Field left as SVP & CTO effective March 14, 2025 to pursue other opportunities.
Insulet extends NXP chip supply pact through 2025; OP5 pump terms included
2025 Addendum extends purchase agreement to Dec 31, 2025 with amended pricing and volume.
Insulet approves revised equity agreement forms for fiscal 2025
Talent and Compensation Committee approved revised forms of stock option, RSU, and PSU agreements on Feb 17, 2025.
Insulet FY2024 revenue $2.1B (+22%), beats guidance; GAAP EPS $5.78, adjusted $3.24
FY2024 revenue $2.1B (+22.1% YoY), exceeds constant currency guidance of 20-21%.
Insulet awarded $452M jury verdict against EOFlow for trade secret misappropriation
Jury awarded $170M compensatory and $282M exemplary damages, total $452M, for willful and malicious misappropriation.
Revenue $543.9M (+25.7% YoY); Omnipod $533.6M (+26.4%); U.S. +23.4%, International +36.1%.
Insulet Q2 revenue up 23% to $488.5M, beats guidance; raises FY2024 outlook
Revenue $488.5M (+23.2% YoY), exceeds high end of guidance of 18% constant currency growth.
Insulet refinances $485M term loans, extends maturity to 2031, cuts interest margin by 0.50%
$485M existing term loans replaced with new term loans maturing Aug 2, 2031 (extended from May 2028).
Insulet Q2 preliminary revenue $488M (+23% YoY), raises FY Omnipod guidance to 18-21%
Q2 revenue $488M, up 23% YoY, exceeding guidance of 15-18% constant currency growth.
63,779,026 shares (91.08% quorum) voted at May 22, 2024 meeting.
Insulet amends supply pact with NXP, extending term and clarifying Covid force majeure
Addendum to 2017 Purchase Agreement with NXP USA effective January 1, 2024.
Insulet Q1 revenue $441.7M (+23% YoY); raises full-year guidance
Q1 revenue $441.7M, +23.3% YoY, above guidance of 17-20% constant currency; Omnipod revenue $433.0M.
Insulet appoints Ana Maria Chadwick as CFO effective April 22, 2024
Chadwick, previously CFO of Pitney Bowes, brings 30 years of finance experience.
the Board appointed Ashley McEvoy as President and Chief Executive Officer of the Company and as a member of the Board as a Class III Director.
James R. Hollingshead, who has agreed with the Board that his employment will cease effective as of April 28, 2025, and resigned from the Board.
Mark Field, who had been serving as the Company’s Senior Vice President and Chief Technology Officer, left the Company, effective March 14, 2025.
Mark Field, Senior Vice President, Chief Technology Officer of Insulet Corporation (the “ Company ”) left the Company to pursue other opportunities, effective March 14, 2025.
Amit Guliani, currently serving as Group Vice President, Software Engineering, will serve as acting Chief Technology Officer, effective immediately.
Lauren Budden, who has been serving as the Company’s Interim CFO and Treasurer, will step down as Interim CFO and Treasurer and continue in her role as Group Vice President, Chief Accounting Officer and Controller.
On March 20, 2024, Insulet Corporation (the “ Company ”) announced the appointment, effective April 22, 2024, of Ana Maria Chadwick to serve as Executive Vice President, Chief Financial Officer (“CFO”) and Treasurer.
Max materiality 0.85 · Median 0.62 · Most common event earnings